Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 0 | $0 |
| Sells | 163 | $110,289,482 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 14 Nov 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | President | 12 Nov 2024 | Sale | 15,105 | 88.72 | 1,340,116 | D |
| 14 Nov 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | President | 12 Nov 2024 | Sale | 6,116 | 89.63 | 548,177 | D |
| 14 Nov 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | President | 12 Nov 2024 | Sale | 1,648 | 90.89 | 149,787 | D |
| 14 Nov 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | President | 13 Nov 2024 | Sale | 13,371 | 88.17 | 1,178,921 | D |
| 14 Nov 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | President | 13 Nov 2024 | Sale | 5,343 | 88.92 | 475,100 | D |
| 30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 30 Aug 2024 | Sale | 6,193 | 73.3232 | 454,091 | D |
| 30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 30 Aug 2024 | Sale | 28,203 | 72.732 | 2,051,261 | D |
| 30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 29 Aug 2024 | Sale | 5,772 | 73.2451 | 422,771 | D |
| 30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 29 Aug 2024 | Sale | 29,832 | 72.4428 | 2,161,114 | D |
| 28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 28 Aug 2024 | Sale | 240 | 73.7 | 17,688 | D |
| 28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 28 Aug 2024 | Sale | 32,459 | 72.7414 | 2,361,113 | D |
| 28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 27 Aug 2024 | Sale | 16,856 | 73.9316 | 1,246,191 | D |
| 28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 26 Aug 2024 | Sale | 22,713 | 74.5929 | 1,694,229 | D |
| 28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 27 Aug 2024 | Sale | 23,657 | 73.3341 | 1,734,865 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 23 Aug 2024 | Sale | 28,680 | 74.4573 | 2,135,435 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 22 Aug 2024 | Sale | 4,369 | 75.4697 | 329,727 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 22 Aug 2024 | Sale | 35,011 | 74.5787 | 2,611,075 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 1,900 | 77.9805 | 148,163 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 4,297 | 76.2001 | 327,432 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 2,682 | 77.2139 | 207,088 | D |
| 23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 44,134 | 75.4026 | 3,327,818 | D |
| 20 Aug 2024 18:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 16 Aug 2024 | Sale | 18,714 | 75.08 | 1,405,047 | D |
| 25 Jun 2024 18:04 | ITCI | Intra-Cellular Therapies Inc | RIGGS RORY B | Director | 24 Jun 2024 | Sale | 4,462 | 75.57 | 337,193 | D |
| 21 Jun 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 18 Jun 2024 | Sale | 11,109 | 76.07 | 845,062 | D |
| 21 Jun 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 18 Jun 2024 | Sale | 8,891 | 75.71 | 673,138 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 306 | 67.33 | 20,603 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 1,590 | 66.81 | 106,228 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 4,128 | 65.9 | 272,035 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 14,541 | 64.8 | 942,257 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 07 Mar 2024 | Sale | 8,754 | 66.93 | 585,905 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 07 Mar 2024 | Sale | 31,958 | 66.38 | 2,121,372 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 64 | 67.12 | 4,296 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,475 | 66.47 | 297,453 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 29 | 67.32 | 1,952 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 1,100 | 66.54 | 73,194 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,453 | 65.28 | 290,692 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,618 | 66.93 | 442,943 | D |
| 11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,514 | 66.26 | 431,618 | D |
| 11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 1,238 | 66.7 | 82,575 | D |
| 11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 6,107 | 65.82 | 401,963 | D |
| 11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 220 | 66.81 | 14,698 | D |
| 11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 12,912 | 66.14 | 854,000 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,313 | 66.86 | 87,787 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,729 | 65.92 | 113,976 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 4,303 | 65.11 | 280,168 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 4,496 | 66.95 | 301,007 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 8,636 | 66.37 | 573,171 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 661 | 66.96 | 44,261 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 872 | 65.89 | 57,456 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 2,179 | 65.06 | 141,766 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 2,722 | 66.86 | 181,993 | D |
| 11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 3,728 | 66.34 | 247,316 | D |
| 28 Feb 2024 19:41 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 27 Feb 2024 | Sale | 10,349 | 73.14 | 756,926 | D |
| 28 Feb 2024 19:41 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 27 Feb 2024 | Sale | 9,651 | 72.71 | 701,724 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 392 | 70.13 | 27,491 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 7,215 | 69.54 | 501,731 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 300 | 68.54 | 20,562 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 600 | 69.81 | 41,886 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 5,282 | 69.47 | 366,941 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 288 | 70.15 | 20,203 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 6,867 | 69.38 | 476,432 | D |
| 27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 300 | 68.33 | 20,499 | D |
| 27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 12,462 | 70.11 | 873,711 | D |
| 27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 9,528 | 69.45 | 661,720 | D |
| 27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 600 | 68.39 | 41,034 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,312 | 71.02 | 93,178 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 70.16 | 98,224 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 69.38 | 97,132 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 1,307 | 71.18 | 93,032 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 2,341 | 70.7 | 165,509 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 4,059 | 69.56 | 282,344 | D |
| 27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 200 | 68.03 | 13,606 | D |
| 27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 299 | 69.6 | 20,810 | D |
| 27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 17,658 | 69.07 | 1,219,638 | D |
| 27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 8,371 | 67.83 | 567,805 | D |
| 05 Feb 2024 18:13 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 02 Feb 2024 | Sale | 714 | 67.17 | 47,959 | D |
| 05 Feb 2024 18:13 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 02 Feb 2024 | Sale | 11,146 | 66.37 | 739,760 | D |
| 05 Feb 2024 18:10 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 02 Feb 2024 | Sale | 17,450 | 67.42 | 1,176,479 | D |
| 05 Feb 2024 18:10 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 02 Feb 2024 | Sale | 16,435 | 66.7 | 1,096,214 | D |
| 05 Feb 2024 18:07 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 02 Feb 2024 | Sale | 6,904 | 67.49 | 465,951 | D |
| 05 Feb 2024 18:07 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 02 Feb 2024 | Sale | 4,956 | 66.67 | 330,417 | D |
| 05 Feb 2024 18:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 02 Feb 2024 | Sale | 185 | 67.35 | 12,460 | D |
| 05 Feb 2024 18:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 02 Feb 2024 | Sale | 10,998 | 66.61 | 732,577 | D |
| 05 Feb 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Feb 2024 | Sale | 3,847 | 67.49 | 259,634 | D |
| 05 Feb 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Feb 2024 | Sale | 2,320 | 66.69 | 154,721 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Jan 2024 | Sale | 320 | 66.25 | 21,200 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Jan 2024 | Sale | 67,597 | 65.19 | 4,406,648 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 17 Jan 2024 | Sale | 17,451 | 66.66 | 1,163,284 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 17 Jan 2024 | Sale | 30,633 | 66 | 2,021,778 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 5,882 | 67.76 | 398,564 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 65,979 | 67.25 | 4,437,088 | D |
| 18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 3,500 | 66.38 | 232,330 | D |
| 12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 1,486 | 67.8 | 100,751 | D |
| 12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 30,360 | 67.1 | 2,037,156 | D |
| 12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 18,154 | 66.31 | 1,203,792 | D |
| 04 Jan 2024 19:54 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Jan 2024 | Sale | 2,210 | 71.77 | 158,612 | D |
| 04 Jan 2024 19:54 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Jan 2024 | Sale | 22,645 | 70.8 | 1,603,266 | D |
| 04 Jan 2024 19:54 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Jan 2024 | Sale | 37,427 | 70.41 | 2,635,235 | D |
| 15 Dec 2023 17:01 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Dec 2023 | Sale | 21,262 | 65 | 1,382,030 | D |
| 14 Nov 2023 17:33 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Nov 2023 | Sale | 8,933 | 53.37 | 476,754 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)